Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Abbott Laboratories (ABT : NYSE)
 
 • Company Description   
Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson.

Number of Employees: 113,000

 
 • Price / Volume Information   
Yesterday's Closing Price: $109.88 Daily Weekly Monthly
20 Day Moving Average: 5,743,945 shares
Shares Outstanding: 1,750.94 (millions)
Market Capitalization: $192,393.55 (millions)
Beta: 0.73
52 Week High: $142.60
52 Week Low: $104.63
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -6.64% 1.92%
12 Week -5.92% 1.68%
Year To Date -21.93% -7.52%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
100 ABBOTT PARK ROAD
-
ABBOTT PARK,IL 60064
USA
ph: 224-667-6100
fax: 847-937-1511
None http://www.abbott.com
 
 • General Corporate Information   
Officers
Robert B. Ford - Chief Executive Officer and Chairman of the Board
Robert E. Funck - Executive Vice President; Finance and Chief Financ
Hubert L. Allen - Executive Vice President; General Counsel and Secr
Philip P. Boudreau - Vice President; Finance and Controller
Robert J. Alpern - Director

Peer Information
Abbott Laboratories (BJCT)
Abbott Laboratories (CADMQ)
Abbott Laboratories (APNO)
Abbott Laboratories (UPDC)
Abbott Laboratories (IMTIQ)
Abbott Laboratories (CYGN)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED PRODUCTS
Sector: Medical
CUSIP: 002824100
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 07/28/22
Share - Related Items
Shares Outstanding: 1,750.94
Most Recent Split Date: 6.00 (2.00:1)
Beta: 0.73
Market Capitalization: $192,393.55 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 1.71%
Current Fiscal Quarter EPS Consensus Estimate: $1.11 Indicated Annual Dividend: $1.88
Current Fiscal Year EPS Consensus Estimate: $4.82 Payout Ratio: 0.33
Number of Estimates in the Fiscal Year Consensus: 9.00 Change In Payout Ratio: -0.07
Estmated Long-Term EPS Growth Rate: 7.83% Last Dividend Paid: 04/13/2022 - $0.47
Next EPS Report Date: 07/28/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 22.81
Trailing 12 Months: 19.55
PEG Ratio: 2.91
Price Ratios
Price/Book: 5.40
Price/Cash Flow: 15.06
Price / Sales: 4.32
EPS Growth
vs. Year Ago Period: 31.06%
vs. Previous Quarter: 31.06%
Sales Growth
vs. Year Ago Period: 13.76%
vs. Previous Quarter: 3.72%
ROE
03/31/22 - 28.72
12/31/21 - 27.06
09/30/21 - 28.39
ROA
03/31/22 - 13.60
12/31/21 - 12.70
09/30/21 - 13.15
Current Ratio
03/31/22 - 1.85
12/31/21 - 1.85
09/30/21 - 1.83
Quick Ratio
03/31/22 - 1.40
12/31/21 - 1.46
09/30/21 - 1.42
Operating Margin
03/31/22 - 22.64
12/31/21 - 21.75
09/30/21 - 22.72
Net Margin
03/31/22 - 17.35
12/31/21 - 16.42
09/30/21 - 17.12
Pre-Tax Margin
03/31/22 - 20.32
12/31/21 - 19.06
09/30/21 - 19.55
Book Value
03/31/22 - 20.35
12/31/21 - 20.37
09/30/21 - 19.59
Inventory Turnover
03/31/22 - 3.55
12/31/21 - 3.49
09/30/21 - 3.46
Debt-to-Equity
03/31/22 - 0.48
12/31/21 - 0.48
09/30/21 - 0.50
Debt-to-Capital
03/31/22 - 32.41
12/31/21 - 32.44
09/30/21 - 33.50
 

Powered by Zacks Investment Research ©